Weixinkang released its 2026 interim report. The company's total operating revenue was 584 million yuan, down 0.32% from the same period last year. Net profit attributable to the parent was 143 million yuan, down 21.81% year-on-year. Net cash inflow from operating activities was 163 million yuan. The asset-liability ratio was 21.57%, gross margin was 59.13%, ROE was 9.28%, and diluted earnings per share was 0.33 yuan. The company had 14,200 shareholders, and the top ten shareholders held 78.39% of total share capital.
Tibet Weixinkang Medicine Co LtdNet profit fell 21.81% year-on-year, missing expectations.
